Joint Venture and Patent Grant Mark Jointechlabs’ Entry Into China Regenerative Medicine Microfat Market

China focus includes a joint venture with a top Shanghai/Suzhou-based medical technology company and the granting of a core Chinese patent covering microfat (adipose tissue) processing.

BRANDON, FL, OCT. 2, 2023/PRNewswire. Jointechlabs, Inc., a Regenerative Medicine Solutions company announced that it has been granted a core patent by the China National Intellectual Property Administration covering adipose tissue processing and has entered into a joint venture with Bangyi Medical Technology Co., Ltd. to develop the aesthetic, plastic surgery, and orthopedic-sports medicine market in China.

The China Patent

Jointechlabs’ unique technology is designed to enable health practitioners worldwide to utilize autologous adipose tissue and its derivates (a person’s own fat) for joint pain relief and a wide variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications.

Patent CN115722351A titled “SYSTEM AND METHODS FOR PREPARATION OF ADIPOSE-DERIVED STEM CELLS” has been granted. This patent addresses the core operation and features of MiniTC®, the company’s flagship adipose processing system. The patent covers MiniTC’s technological superiority including industry-leading microfat purity, quantity, and processing speed.

“Innovation and market depth are both key to our success and strategy as a pioneer and leader of the regenerative medicine industry,” said Dr. Nathan Katz, CEO of Jointechlabs. “This patent strengthens our global intellectual property portfolio and allows us to bring our innovations to the Chinese public.”

Jointechlabs has a portfolio of worldwide patents in jurisdictions including China, the United States, EU, Israel, Japan, and Ukraine.

*Celebrating the inauguration of Zann Medical*

The Partnership

Jointechlabs also announced Zann Medical Technology Co., Ltd., a joint venture agreement with Bangyi Medical Technology Co., Ltd., a leading provider of medical technology solutions in China. With this agreement, Zann Medical will market and distribute Jointechlabs’ regenerative medicine products in China. In this partnership, Jointechlabs will provide licensed technology, training, manufacturing knowhow, and technical support. Correspondingly, Bangyi will market, sell, train, service, and support the licensed products. The Bangyi distribution network includes over 50 representatives and 500 distributors servicing over 600 hospitals and medical practices.

Dr. Nishit Pancholi, COO of Jointechlabs said “Bangyi is the right partner to help us bring our regenerative medicine solutions to China for the benefit of so many aesthetic, plastic surgery, and orthopedic-sports medicine patients. Therefore, we look forward to serving the needs of the Chinese population and the medical community.”

Jerry Luo, Chairman of the Board and co-founder of Bangyi, said “We forecast significant demand for MiniTC and Jointechlabs products throughout China.” Simon Chen, Managing Director and co-founder added “Accordingly we are excited to work with Jointechlabs and together address regenerative medicine needs throughout China.”

About Jointechlabs

Headquartered in Brandon, FL, privately-held Jointechlabs is an emerging worldwide leader in regenerative medicine. The company enables healthcare practitioners to provide safe, cost-effective, non-surgical therapies at the point-of-care without change in infrastructure.

FDA-cleared MiniTC® is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat. Microfat’s uses include a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Additionally, in certain markets, CE-Mark-pending Mini-Stem System® extracts microfat and Stromal Vascular Fraction.

Pipeline includes development of stem-cell based therapeutics with 3D Bioprinted constructs and injectable stem cell scaffolding.

More Information: https://www.jointechlabs.com.

Contact: nishit.pancholi@jointechlabs.com.

Best Practices Adipose Presentation for Practitioners

For people new to microfat as well as for experienced clinicians

Dr. Nathan Katz, adipose tissue expert and CEO of Jointechlabs, discusses the scientific basis for the use of adipose tissue and microfat in regenerative medicine and discusses best practices in microfat-based procedures and the processing of microfat for optimal results.

Dr. Nathan Katz, speaker in this best practices presentation. — *Dr. Nathan Katz, CEO, Jointechlabs, Inc.*

This presentation is designed both for doctors who are new to microfat and/or regenerative medicine and for doctors who use microfat and want to understand best practices.

Read Dr. Katz’s bio here: https://jointechlabs.com/about/

The following is a transcript of the first portion of the best practices presentation:

“Hello, I’m Nathan Katz.

I’m going to talk today about

fat – like you can see on my background screen. I have to disclose

that I’m the CEO of a company that is involved in the

development and manufacturing of products in the field of regenerative

medicine, specifically related to the processing of fat. However,

for this presentation, I will try as much as possible to present the scientific

aspects of adipose tissue and the

application of adipose derived products

in the different regenerative medicine applications.

I hold a PhD in biology

and I have medical background.

You can see that we love your fat. It’s our slogan,

and we literally love the fat because fat is a

very potent and very rich human tissue that

if leveraged properly can be applied for different applications;

pain mitigation, aesthetics and wound healing. And that’s

what we do, what industry does, and the

goal to find the proper way, how to apply fat,

how to process fat properly, and how to learn

to deal with the adipose tissue.”

Jointechlabs Makes Microfat-based Regenerative Medical Procedures More Efficient and Profitable

Faster, simpler, and more efficient microfat-based procedures

BRANDON, FL/September 19, 2023 – Designed to save a physician time when performing any microfat-based medical procedure, Jointechlabs, Inc. has optimized the components and process of its industry-leading MiniTC^® Microfat Processing system. These optimizations produce greater patient and doctor satisfaction, increase profitability, and set a new standard for regenerative medicine efficiency.

A microfat-based procedure consists of three phases: removing (harvesting) fat from a patient, processing that fat into microfat, and injecting the microfat back into the patient. MiniTC is the efficiency and quality leader for fat processing, yet physicians demand efficiency throughout the entire procedure. Jointechlabs is meeting this demand with components, automation, and best practice optimization in all three phases.

Below are typical times for each of the above phases in a common knee joint pain procedure showing 2023 efficiency improvements over 35%:

	Fat Harvesting	Microfat Processing	Microfat Reinjection	Procedure Total
2018	30 minutes	30 minutes	20 minutes	80 minutes
2023	15 minutes	25 minutes	10 minutes	50 minutes

*MiniTC® and components – optimized for microfat procedure efficiency.*

FatLok™ – the only syringe on the market formally designed and intended for lipoaspiration

Dr. Ariana DeMers, Orthopedic Surgeon at Restore Orthobiologic, says “One of my favorite parts of MiniTC is the harvester. It’s probably the best one on the market.”

Optimizing the Process, Not Just the Components

In addition to bespoke component design, the company has standardized and further automated the process at each stage of a MiniTC-based procedure, again reducing the labor needed, simplifying training, allowing doctors to easily gain proficiency and other medical professionals to perform much of the process, and leading to consistent results.

“Our goal is to make microfat-based procedures using MiniTC the simplest and most efficient on the market and to move the regenerative medicine industry forward. We are striving to assure a stress-free, time-efficient process, from harvesting through processing to effortless injection.” said Dr. Nathan Katz, Jointechlabs CEO. “Henry Ford had a fantastic vehicle engine in the early 1900s. But it was only when Ford optimized production that motor vehicles changed the world. We see a parallel here.”

Integral to this holistic and efficient approach, Jointechlabs support team will guide and train doctors on best practices. This training covers each of the three phases of microfat-based procedures.

Best practices training for microfat-based procedures using MiniTC^®

“The safety and effectiveness of microfat-based procedures have been shown through years of clinical experience,” said Dr. Nishit Pancholi, COO. “However, for the first time the business case for microfat-based procedures is overwhelming. MiniTC-based procedures are effective and rewarding for the patient, the doctor, and the practice. We are thrilled to be on the forefront of regenerative medicine adoption”

The above enhancements are available immediately.

More information at www.jointechlabs.com and www.linkedin.com/company/jointechlabs.

Contact: 800-217-0491 info@jointechlabs.com.

MiniTC Adipose System Now Faster, More Convenient, Personalized

MiniTC Adipose Processing System and its components

New syringes and a choice of cannulas will make adipose processing faster and personalized to each physician’s needs.

CHICAGO/April 4, 2023 – Jointechlabs, Inc., a privately held US-based regenerative medicine and therapeutics company, today announced upgraded syringes and cannulas that ship with the acclaimed MiniTC and Mini-Stem Adipose Processing systems.

The syringe upgrade provides faster and more efficient harvesting and precise input into and output from the MiniTC device. Additionally, it is FDA-cleared for lipoaspiration.

The additional cannula (lipoaspirate harvester) allows for faster harvesting, yet preserves the high yield ratio of the MiniTC grafting protocol. This second cannula provides the physician with a choice of cannulas based on personal preference.

“Many physicians have said that MiniTC’s current, Sorenson-style cannula is their choice for adipose harvesting, in particular for fibrous and/or lean adipose tissue,” said Dr. Nathan Katz, Jointechlabs CEO. “But others have told us they prefer a faster cannula that reduces harvesting time. By providing a choice with every MiniTC, physicians can now choose the cannula they prefer for virtually any type of patient body structure.”

Dr. Ariana DeMers, Orthopedic Surgeon at Restore Orthobiologic, says “One of my favorite parts of MiniTC is the harvester. It’s probably the best one on the market.”

This upgrade is effective immediately. Any physician with existing inventory who would like the new syringes and cannula can contact the company at https://jointechlabs.com/contact.

About Jointechlabs

Privately-held Jointechlabs is an emerging worldwide leader in point-of-care regenerative medicine. Jointechlabs enables healthcare practitioners and hospitals to provide safe, cost-effective, non-surgical regenerative medicine therapies at the point-of-care without change in infrastructure.
FDA-cleared MiniTC® for the US market is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-pending Mini-Stem System® prepares Microfat and also extracts Stromal Vascular Fraction.
Pipeline products include stem-cell therapeutics such as Bioprinting and injectable stem cell scaffolding.
More information at www.jointechlabs.com

MDSAP Quality Certification Awarded to Jointechlabs

Medical Device Single Audit Program (MDSAP) certification applies to the United States, Canada, Australia, Brazil, and Japan.

MDSAP Certification for Jointechlabs, Inc.

CHICAGO/March 15, 2023 – Jointechlabs, Inc., a privately held US-based regenerative medicine and therapeutics company, today announced it has been granted an MDSAP certification for its quality management system that satisfies the requirements of multiple regulatory jurisdictions. These jurisdictions include the United States, Canada, Australia, Brazil, and Japan.

The MDSAP allows medical device manufacturers to be audited once for compliance with multiple jurisdictions’ standards and regulatory requirements. The program’s main mission is to “…jointly leverage regulatory resources to manage an efficient, effective, and sustainable single audit program focused on the oversight of medical device manufacturers.”

To earn this certification, Jointechlabs underwent a comprehensive audit by a regulatory body. The company demonstrated that its quality management and manufacturing systems conform to the exacting standards of ISO 13485:2016. ISO 13485:2016 is the most recent and rigorous 13485 standard for medical device manufacturers. The requirements cover quality systems, management, and the entire medical device product journey from conceptualization to implementation. Additionally, customer support, event reporting, continuous improvement, and regular product evaluation are components.

“We are thrilled and honored to earn this MDSAP quality certification,” said Dr. Nishit Pancholi, COO of Jointechlabs. “Quality is a core company value and one of the things that set us apart. Moreover, producing the purest, highest quality biologics allows our customers to achieve the best outcome at the lowest risk.”

The MDSAP certification is not mandatory for medical device manufacturers. There is no publicly available listing of companies who are MDSAP certified. However, companies who earn the certification generally make their status known.

More information from the US F.D.A. is available at https://www.fda.gov/medical-devices/cdrh-international-programs/medical-device-single-audit-program-mdsap

Jointechlabs launches European expansion with new partnerships, grants, and subsidiary

European focus includes a new subsidiary in Austria, a medical research center in partnership with a prominent health center, and development and distribution agreements for Germany, Austria, Switzerland, Italy, Spain, and the Balkans.

CHICAGO, OCT. 20, 2022/PRNewswire/–Jointechlabs, Inc., a Regenerative Medicine Solutions company announced a Vienna-based subsidiary named JointechPlus GmbH. They also announced research, development, and clinical partnerships with Laakirchner Gesundheitszentrum (LGZ), a multispecialty health center in Upper Austria, and Educell, a Slovenian biotech company. New distribution partners include R.E.N.G. GmbH and Eywa S.r.l., while a new grant has been secured from the Slovenian government.

JointechPlus

“JointechPlus (http://www.jointechplus.at/) allows us to develop and market products for and in cooperation with the European community,” said Dr. Nathan Katz, CEO of Jointechlabs. “We are thrilled to welcome our European partners and investors in our drive to bring regenerative medicine solutions to Europe and the world,” said Dr. Nishit Pancholi, COO of Jointechlabs.

Research, Development, and Clinical Partnerships

JointechPlus has formed a partnership with LGZ (https://www.lgz.co.at/) to establish a medical research center that will be the hub for regenerative medicine solutions, focusing on orthopedic and wound healing therapeutic biologics.

Mr. Christian F. Albrecht, Managing Director at LGZ, said “Our partnership with JointechPlus allows us to bring advanced regenerative medicine solutions to our patients, while expanding our ability to educate and train medical professionals in this fast-growing field.”

Slovenia-based Educell (https:/www.educell.si/en/) has expertise in adipose-derived stem cells, and an extensive clinical network in the Balkans. The partnership has secured a grant from the Slovenian government, positioning Jointechlabs and Educell to be the leaders in point-of-care adipose-based solutions in the Balkans.

Distribution Partnerships

The distribution agreements focus on Jointechlabs’ adipose processing systems MiniTC® and Mini-Stem System®. The R.E.N.G. GmbH agreement covers Germany, Austria, and Switzerland, while the agreement with Eywa S.r.l. covers Italy and Spain.

About Jointechlabs

Headquartered in Chicago, IL, privately-held Jointechlabs is an emerging worldwide leader in regenerative medicine, enabling healthcare practitioners to provide safe, cost-effective, non-surgical regenerative medicine therapies at the point of care without change in infrastructure.

FDA-cleared MiniTC® is a stand-alone device for processing autologous fat into regenerative-cell-rich Microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-pending Mini-Stem System® extracts Microfat and Stromal Vascular Fraction.

The pipeline includes the development of stem-cell-based therapeutics with 3D Bioprinted constructs and injectable stem-cell scaffolding.

More information at www.jointechlabs.com and www.linkedin.com/company/jointechlabs.
Contact: info@jointechlabs.com.

Jointechlabs is Granted Additional Patent for Innovations Using Adipose in Regenerative Medicine Applications

Chicago, Ill, October 3, 2022/ — Jointechlabs, a global leader in point-of-care regenerative medicine, was issued US Patent No. 11,447,748, “Encapsulated Adipose-Derived Stem Cells, Methods for Preparation and Therapeutic Use,” the third utility patent in a family of patents, securing the intellectual property portfolio towards planned development steps.

“Innovation is a cornerstone of our success and strategy as a pioneer and leader of the regenerative medicine industry,” said Dr. Nathan Katz, CEO of Jointechlabs. “This patent strengths the IP basis of our therapeutic development leveraging the already commercially available MiniTC® and Mini-Stem System® platform family. Securing a solid IP portfolio demonstrates both our commitment to innovation and our ability to secure patent protection in a way that strengthens our leadership and our competitive advantage.”

This latest patent covers methods and systems of encapsulating mesenchymal stem cells in a three-dimensional biocompatible gel matrix, maintaining the viability and location of the stem cells for an extended period, a significant advantage for therapeutic treatment efficacy as compared to stem cells in suspension.

Jointechlabs has a portfolio of 12 US and foreign patents. The latest patent joins the family that includes US Patent Nos 9,931,445, 9,938,501, and 10,745,666, issued between 2018 and 2020, with 11,447,748 extending coverage through 2032. Other patents have been granted in China, EU, Israel, Japan, and Ukraine.

Dr. Nishit Pancholi, COO of Jointechlabs added “We are gratified to have earned this latest patent, further memorializing our innovation, which continues to be validated by the global marketplace success of our products.”

About Jointechlabs

Headquartered in Chicago, IL, privately-held Jointechlabs is an emerging worldwide leader in point-of-care regenerative medicine, enabling healthcare practitioners and hospitals provide safe, cost-effective, non-surgical regenerative medicine therapies at the point-of-care without change in infrastructure.
FDA-cleared MiniTC® for the US market is a stand-alone device for processing autologous fat into regenerative-cell-rich Microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-pending Mini-Stem System® prepares Microfat and also extracts Stromal Vascular Fraction.
Pipeline products include stem-cell therapeutics such as Bioprinting and injectable stem cell scaffolding.
More information at www.jointechlabs.com and www.linkedin.com/company/jointechlabs.
Contact: info@jointechlabs.com.

###

Jointechlabs’ MiniTC Training by Dr. Nathan Katz, Ph.D., and Dr. Enrico Guarino

Jointechlabs is an emerging leader in the field of outpatient autologous regenerative and rejuvenating therapies.

The recent commercial launch of the MiniTC® device is causing disruptive waves across the industry. This unique sleekly designed disposable and multifunctional product offers uncomparable simplicity, convenience, and quality altogether.

Jointechlabs genuinely integrates its technology into the existing workflows of healthcare providers, expanding treatment options and bringing the next generation of therapeutics down to everyday medical practice for the whole benefit of patients and communities.

Here is one of the most recent pieces of training for the application of MiniTC-manufactured microfat grafts in the Chicago area.

Guided Lymphangiogenesis for the Treatment of Lymphedema: Preliminary Clinical Results

Catarina Hadamitzky, Tatiana S. Zaitseva, Nathan Katz, Claire P Edelstein, Manuel T. Escarraman, Dung Nguyen, Michael V. Paukshto

Clinic of Plastic, Aesthetic and Hand Surgery, Helios Clinic, Hildesheim, Germany.

Fibralign Corporation, Union City, California, USA.

JointechLabs, Inc, N. Barrington, Illinois, USA.

Instituto Oncológico Dr. Heriberto Pieter, Santo Domingo, Dominican Republic.

Department of Plastic Surgery, Stanford University, Stanford, California, USA.

To address the limitations of current treatments for secondary lymphedema, our study group developed an experimental surgical procedure based on Autologous Lymph Node Fragment (ALNF) transfer supplemented by nanofibrillar collagen scaffold with and without autologous Adipose-Derived Stromal Cells out from the stromal vascular fraction (ADSCs). The efficacy of this scaffold was demonstrated before in a porcine model of secondary lymphedema. To address the challenges of poor survival and low migration from the injection site described in clinical studies of ADSCs, we used ADSC-seeded scaffolds to deliver the cells. These scaffolds seem to support cell survival, maintenance, and function at the targeted site. The ongoing pilot study has 12 patients currently enrolled. We used non-vascularized autologous lymph node fragment transfer (LNFT) as a basic treatment for all patients. It was supplemented by implantation of: BioBridge scaffolds (n=5); BioBridge scaffolds with ADSCs (n=2); BioBridge scaffolds with injected ADSCs (n=1); and injected ADSCs only (n=4; control group still ongoing). In the therapy groups, no complications have been reported after almost one year. 6 of 8 patients using BioBridge responded to the treatment after 6 months with an average volume reduction of about 20%. Two of these patients have attained a normal limb volume ratio (≤1.1) at 3 months after surgery. The average edema reduction in the control group (n=4) was only 1.1% 4 months after surgery. More data will be presented at the time of the conference. While vascularized lymph node transfer is considered to be a more advanced technique than ALNF transfer, there is a great interest in developing countries to have simpler surgery to manage lymphedema without the need for a microscope. On the other hand, the concept of guiding lymphangiogenesis with collagen scaffolds could also potentially improve the efficiency of well-established vascularized lymph node procedures.

3D Bioprinting of Autologous Adipose Tissue for Wound Healing

Critical skin wounds are a major cost for the health sector and lead to immense suffering for the patients. One way to facilitate the healing of these wounds is through autologous adipose tissue transplants. However, the implanted tissue needs to be vascularized or it will suffer from necrosis. To combat this Stromal vascular fraction (SVF), which is isolated from fat, can be utilized as it has been shown to promote both vascularization and the wound healing process. In this project, we evaluate a method that combines SVF with 3D Bioprinting to create thick fat grafts for in situ vascularization.

METHODS:

Adipose tissue was taken with consent from patients undergoing plastic surgery and was isolated with MiniStem, the device from JoinTechLabs, USA. Two MiniStem protocols were run: (i) lipoaspirate was fractured toward macerated fat graft and (ii) lipoaspirate was enzymatically treated in order for SVF harvest. Collected SVF was analyzed with FACS. Both fractions were mixed with a hydrogel composed of a mix of nanocellulose and alginate. The resulting cell-laden hydrogels (bioinks) were 3D Bioprinted as gridded constructs with CELLINKs INKREDIBLE+ bioprinter. The properties of the final constructs and bioinks were evaluated from a rheological perspective using a rheometer and O-prints, a method developed in-house.

RESULTS:

The o-print showed that the mixed hydrogels were homogenous and easily printable. Rheology testing revealed that the crosslinked bioink also displayed properties like that of the extracellular matrix. FACS of the extracted SVF fractions showed the presence of a heterogeneous cell population with a substantial presence of ASCs, pericytes, and endothelial progenitors.

FACS data for SVF isolated with Ministem

DISCUSSION & CONCLUSIONS:

We have shown that we can isolate both fat and SVF from the same liposuction procedure. These results also show that fat and SVF isolated with the MiniStem and mixed with biopolymers contain relevant cells and possess good printability. High expression of angiogenic markers in both protocols strongly indicates potential angiogenic capacity.